Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Source: SeekingAlpha
2026-03-04 06:57:42 ET
More on Sanofi, Sino Biopharmaceutical Limited
- Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
- Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
- Sanofi 2025 Q4 - Results - Earnings Call Presentation
- Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
- Sanofi anticipates profitable growth to continue over at least five years
Read the full article on Seeking Alpha
For further details see:
Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Sino Biopharmaceutical Ltd ADR
NASDAQ: SBHMY
SBHMY Trading
-64.76% G/L:
$17.65 Last:
100 Volume:
$17.65 Open:
